Long circulating PEGylated PLGA nanoparticles of cytarabine for targeting leukemia

References

• Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Livaniou E, Evangelatos G, Ithakissios DS. Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA–mPEG nanoparticles. Int J Pharm 2003; 259: 115–27
   PubMed Web of Science ®Google Scholar
• Bala I, Hariharan S, Kumar MN. PLGA nanoparticles in drug delivery: The state of the art. Critical Rev Therapeutic Drug Carrier Syst 2004; 21: 387–422
   PubMed Web of Science ®Google Scholar
• Banerjee T, Singh AK, Sharma RK, Maitra AN. Labeling efficiency and biodistribution of Technetium-99m labeled nanoparticles: Interference by colloidal tin oxide particles. Int J Pharm 2005; 289: 189–95
   PubMedGoogle Scholar
• Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Delivery Rev 2002; 54: 631–51
   PubMed Web of Science ®Google Scholar
• Cole SP. Rapid chemosensitivity testing of human lung tumor cells using the MTT assay. Cancer Chemoth Pharm 1986; 17: 259–63
   PubMed Web of Science ®Google Scholar
• Couvreur P, Dubernet C, Puisieux F. Controlled drug delivery with nanoparticles: Current possibilities and future trend. Eur J Pharm Biopharm 1995; 41: 2–13
   Web of Science ®Google Scholar
• Goppert TM, Muller RH. Plasma protein adsorption of tween 80 and poloxamer 188 stabilized solid lipid nanoparticles. J Drug Target 2003; 11(4)225–31
   PubMedGoogle Scholar
• Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchillin V, Langer R. Biodegradable long circulating polymeric nanospheres. Science 1994; 263: 1600–3
   PubMed Web of Science ®Google Scholar
• Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urologic Oncology: Seminars and Original Investigations 2008; 26: 57–64
   PubMed Web of Science ®Google Scholar
• Ho DHW, Frei E. Clinical pharmacology of 1-B-D arabinofuranosylcytosine. Clin Pharmacol Ther 1971; 12: 944–54
   PubMed Web of Science ®Google Scholar
• Hocking RR. Analysis and selection of variables in linear regression. Biometrics 1976; 32: 1–49
   Web of Science ®Google Scholar
• Illum L, Davis SS. The organ uplakc of Intravenously administered colloidal particles can be altered using a non-ionic surfactant (poloxamer 338). FEBS Lett 1984; 167: 79–82
   PubMed Web of Science ®Google Scholar
• Konan YN, Cerny R, Favet J, Berton M, Gurny R, Allemann E. Preparation and characterization of sterile sub-200nm meso-tetra(4-hydroxylphenyl)porphyrin-loaded nanoparticles for photodynamic therapy. Eur J Pharm Biopharm 2003; 55(1)115–24
   PubMedGoogle Scholar
• Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm 1983; 15: 25–35
   Web of Science ®Google Scholar
• Lamprecht A, Ubrich N, Hombreiro PM, Lehr CM, Hoffman M, Maincent P. Influences of process parameters on nanoparticle preparation performed by a double emulsion pressure homogenization technique. Int J Pharm 2000; 196: 177–82
   PubMed Web of Science ®Google Scholar
• Levy MY, Benita S. Drug release from submicronized o/w emulsion: A new in vitro kinetic evaluation model. Int J Pharm 1990; 66: 29–37
   Web of Science ®Google Scholar
• Mehta AK, Yadav KS, Sawant KK. Nimodipine loaded PLGA nanoparticles: Formulation optimization using factorial design, characterization and in vitro evaluation. Curr Drug Del 2007; 4(3)185–93
   PubMedGoogle Scholar
• Mishra PR, Jain NK. Folate conjugated doxorubicin-loaded membrane vesicles for improved cancer therapy. Drug Del 2003; 10: 277–82
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Davis SS. Innovations in avoiding particle clearance from blood by Kupffer cells: Some cause for reflection. Critical Rev Therapeutic Drug Carrier Syst 1994; 11: 31–59
   PubMed Web of Science ®Google Scholar
• Moghimi SM, Hunter AC, Murray JC. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol Rev 2001; 53: 283–318
   PubMed Web of Science ®Google Scholar
• Panagi Z, Beletsi A, Evangelatos G, Livaniou E, Ithakissios DS, Avgoustakis K. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA–mPEG nanoparticles. Int J Pharm 2001; 221: 143–52
   PubMed Web of Science ®Google Scholar
• Panyam J, Labhasetwar V. Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. Mol Pharm 2004; 1: 77–84
   PubMed Web of Science ®Google Scholar
• Park W, Kim K, Bae B, Kim Y, Na K. Cancer cell specific targeting of nanogels from acetylated hyaluronic acid with low molecular weight. Eur J Pharm Sci 2010; 40(2010)367–75
   PubMedGoogle Scholar
• Peppas NA. Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv 1985; 60: 110–11
   PubMedGoogle Scholar
• Prabha S, Labhasetwar V. Critical determinants in PLGA/PLA nanoparticle- mediated gene expression. Pharm Res 2004; 21: 354–64
   PubMed Web of Science ®Google Scholar
• Reddy LH, Sharma RK, Chuttani K, Mishra AK, Murthy RR. Etoposide incorporated tripalmitin nanoparticles with different surface charge: Formulation, characterization, radiolabeling, and biodistribution studies. AAPS J 2004; 6(3)e23
   PubMedGoogle Scholar
• Segawa H, Kimura S, Kuroda J, Sato K, Nogawa M, Yuasa T, Yokota A, Hodohara K, Fujiyama Y, Maekawa T. The anti-leukemic efficacy of the third generation bisphosphonate ONO5920/YM529. Leuk Res 2005; 29: 451–7
   PubMed Web of Science ®Google Scholar
• Soppimath KS, Aminabhavi T, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Controlled Release 2001; 70: 1–20
   PubMed Web of Science ®Google Scholar
• Stolnik S, Dunn SE, Garnett MC, Davies MC, Coombes AGA, Taylor DC, Irving MP, Purkiss SC, Tadros TF, Davis SS, et al. Surface modification of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)-poly(ethylene glycol) copolymers. Pharm Res 1994; 11: 1800–8
   PubMed Web of Science ®Google Scholar
• Theobald AE. Quality control of radiopharmaceuticals. Text book of radiopharmacy: Theory and practice, CB Sampson. Gordon and Breach, New York 1990; 127–9
   Google Scholar
• Vandervoort J, Yoncheva K, Ludwig A. Influence of the homogenisation procedure on the physicochemical properties of PLGA nanoparticles. Chem Pharma Bull 2004; 52(11)1273–9
   PubMedGoogle Scholar
• Yadav KS, Sawant KK. Modified nanoprecipitation method for preparation of cytarabine loaded PLGA nanoparticles. AAPS Pharm Sci Tech 2010a; 11: 1456–65
   PubMed Web of Science ®Google Scholar
• Yadav KS, Sawant KK. Formulation optimization of etoposide loaded PLGA nanoparticles by double factorial design and their evaluation. Curr Drug Del 2010b; 7(1)51–64
   PubMedGoogle Scholar
• Yadav KS, Chuttani K, Mishra AK, Sawant KK. Long-circulating nanoparticles of etoposide using PLGA-MPEG and PLGA-Pluronic block copolymers: Characterization, drug release, blood-clearance, and biodistribution studies. Drug Dev Res 2010; 71: 228–39
   Web of Science ®Google Scholar
• Yadav KS, Chuttani K, Mishra AK, Sawant KK. Effect of size on biodistribution and blood clearance of etoposide loaded PLGA nanoparticles. PDA J Pharm Sci Tech 2011; 65: 131–9
   PubMedGoogle Scholar
• Yoo HS, Park TG. Folate-receptor-targeted delivery of doxorubicin nano-aggregates stabilized by doxorubicin-PEG-folate conjugate. J Control Release 2004; 100: 247–56
   PubMed Web of Science ®Google Scholar
• Zhang Z, Feng SS. The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)–tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials 2006; 27: 4025–33
   PubMed Web of Science ®Google Scholar